相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)
Wilson I. Gonsalves et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
Liang Zhou et al.
BRITISH JOURNAL OF CANCER (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma
Christelle Dousset et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation
Cyrille Touzeau et al.
HAEMATOLOGICA (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2017)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation
Cyrille Touzeau et al.
HAEMATOLOGICA (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
Paul E. Hughes
CANCER RESEARCH (2017)
AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
Alexander W. Hird et al.
CANCER RESEARCH (2017)
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Stephen K. Tahir et al.
BMC CANCER (2017)
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma
Vikas A. Gupta et al.
BLOOD (2017)
BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics
C. Touzeau et al.
LEUKEMIA (2016)
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
S. M. Matulis et al.
LEUKEMIA (2016)
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
R. Bajpai et al.
ONCOGENE (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1
Jia-Nan Gong et al.
BLOOD (2016)
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome
Bruno Royer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
D. C. Phillips et al.
BLOOD CANCER JOURNAL (2015)
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
David Chiron et al.
ONCOTARGET (2015)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia
Aneel Paulus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C. Fernandez de Larrea et al.
LEUKEMIA (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
Apoptotic machinery diversity in multiple myeloma molecular subtypes
Patricia Gomez-Bougie et al.
FRONTIERS IN IMMUNOLOGY (2013)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ABT-737 is highly effective against molecular subgroups of multiple myeloma
Linda Bodet et al.
BLOOD (2011)
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
Alejo A. Morales et al.
BLOOD (2011)
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
L. Bodet et al.
BRITISH JOURNAL OF CANCER (2010)
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
Asher A. Chanan-Khan et al.
LEUKEMIA & LYMPHOMA (2009)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
NATURE REVIEWS CANCER (2008)
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
Suzanne Trudel et al.
BLOOD (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein
NWCJ van de Donk et al.
LEUKEMIA (2003)
Antisense strategy shows that Mcl-1 rather than Bcl-2 or BCI-xL is an essential survival protein of human myeloma cells
S Derenne et al.
BLOOD (2002)
分享论文
